{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu LD"],"funding":["Shanghai Science and Technology Committee","National Key R&D Program of China","National Natural Science Foundation of China","Shanghai Jiao Tong University COVID-19"],"pagination":["980-986"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7799018"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(12)"],"pubmed_abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common featu"],"journal":["Journal of molecular cell biology"],"pubmed_title":["The development of neutralizing antibodies against SARS-CoV-2 and their common features."],"pmcid":["PMC7799018"],"funding_grant_id":["20490760200","81861138014","81622022","31970880","2017YFA0506700","81671634","31722020"],"pubmed_authors":["Yeap LS","Meng FL","Lian C","Liu LD"],"additional_accession":[]},"is_claimable":false,"name":"The development of neutralizing antibodies against SARS-CoV-2 and their common features.","description":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide severe coronavirus disease 2019 (COVID-19) pandemic since December 2019. There is a great demand for effective therapies for the prevention and treatment of COVID-19. Developing therapeutic neutralizing antibodies (NAbs), which could block viral infection, is such a promising approach, as NAbs have been successfully applied to the treatment of other viral infections. The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs, and many of which are now actively tested in clinical trials. Here, we review the approaches applied for SARS-CoV-2 NAb development, and discuss the emerging technologies underlining the antibody discovery. We further summarize the common featu","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2026-04-13T03:07:04.346Z","creation":"2025-04-05T18:57:05.935Z"},"accession":"S-EPMC7799018","cross_references":{"pubmed":["33377928"],"doi":["10.1093/jmcb/mjaa070"]}}